Company Profile
Celltrion, Inc., a biopharmaceutical company provides the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease.
Its portfolio also includes Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia, Herzuma for metastatic breast and gastric cancer, Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease, Vegzelma for metastatic colorectal cancer and non-small cell lung cancer, Omlyclo for Asthma and urticaria, Eydenzelt for diabetic macular edema and wet age-related macular degeneration, Steqeyma for psoriasis and inflammatory bowel disease, Stoboclo/Osenvelt for osteoporosis, Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis, Zymfentra for inflammatory bowel disease, and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms.
The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis
CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. Founded in 2002, the company is headquartered in Incheon, South Korea.